LIBRETTO-432 (NCT04819100) is an ongoing phase III, global, randomized (1:1), double-blind trial to test selpercatinib vs. placebo for 3 years in the adjuvant setting in 170 patients with RET fusion + Stage IB-IIIA NSCLC following the surgery. The gene discussed is RET; the disease is non-small cell lung carcinoma.